MannKind's Afrezza (inhaled insulin) comparable to antidiabetic therapy in lung function tests

Looks like inhaled insulin is looking to make a big move on the treatment market for insulin dependent diabetics. The inhaled insulin is supposed to be much faster reacting but in some people may cause discomfort and other issues in the lungs. However, disuse of the product showed that the lung issues went away. This might give reason for people to try it and drop it if it causes any lung issues. The product is not for everyone but it may eliminate the frequent use of hypodermic needles for some. One of the possible side of effects is weight loss. This is because traditional traditional insulin treatment causes weight gain in some.

Anyhow, thought I would share some news.